1. Home
  2. HROW vs STDN Comparison

HROW vs STDN Comparison

Compare HROW & STDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HROW

Harrow Inc.

N/A

Current Price

$30.61

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Logo Standard Nuclear Inc. Class A Common Stock

STDN

Standard Nuclear Inc. Class A Common Stock

N/A

Current Price

$12.50

Market Cap

1.9B

ML Signal

N/A

Company Overview

Basic Information
Metric
HROW
STDN
Founded
1998
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2008
2026

Fundamental Metrics

Financial Performance
Metric
HROW
STDN
Price
$30.61
$12.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
8
Target Price
★ $65.00
$17.50
AVG Volume (30 Days)
486.5K
★ 514.5K
Earning Date
11-09-2026
08-26-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 71.43
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$28.81
$449.84
Revenue Next Year
$53.97
$251.39
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$28.54
$7.05
52 Week High
$54.98
$17.34

Technical Indicators

Market Signals
Indicator
HROW
STDN
Relative Strength Index (RSI) 27.10 46.56
Support Level $28.54 $11.58
Resistance Level $35.43 $13.73
Average True Range (ATR) 1.25 0.77
MACD -0.21 -0.19
Stochastic Oscillator 11.48 35.12

Price Performance

Historical Comparison
HROW
STDN

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

About STDN Standard Nuclear Inc. Class A Common Stock

Standard Nuclear Inc is an independent advanced nuclear fuel company. The company designs, engineers, and manufactures advanced nuclear fuels, with a primary focus on TRISO fuel for advanced reactors. Its operations include industrial-scale TRISO fuel manufacturing and the development of fuel for advanced reactors that utilize TRISO fuel. The company operates in a single operating and reportable segment, as it is engaged in a single business activity of TRISO production. It derives revenue from fuel development and services agreements. Geographically, the maximum revenue is generated from the United States.

Share on Social Networks: